Skip to content

Huawei shenanigans and Canopy Growth’s new acquisition


Huawei shenanigans

So it seems that Chinese telecoms company Huawei’s nightmares continue to get worse as three British firms have announced that they will be cutting ties with it.

Although Vodafone and EE saying that they won’t be promoting Huawei handsets as part of their 5G push is a significant inconvenience, the fact that British chipmaker Arm has said that it will stop licensing key chip technology to Huawei is a much more serious problem.

The Chinese company said that it will just start making its own chips, but this latest development will certainly hurt.

Clearly this is all related to Trump putting pressure on the Chinese, but the problem is that his actions could be pushing the Chinese to become more self-sufficient in the long-run, thus potentially closing off that market completely in years to come for foreigners.

I bet that Apple’s not particularly pleased with all this given their ambitions in China and the strong likelihood that it will itself become a political football as part of the current Trump-Xi shenanigans.

Canopy Growth’s new acquisition

The other thing I wanted to talk about today was Canadian cannabis company Canopy Growth’s acquisition of British beauty brand The Works for £43m.

This will see a launch of new products that will be infused with cannabis ingredient CBD that will help users sleep and improve their skin.

The Works is at pains to say on its website that CBD is non-psychoactive and is one of two major substances associated with cannabis plants.

CBD, or Cannabidiol, is a non-intoxicating chemical compound that is supposedly good for “wellness” and skin health and THC is the other ingredient – and the one that gives marijuana its high.

Canopy Growth will use its financial power to help This Works expand internationally.

This is an interesting example of where CBD can be used in addition to other products such as beverages. It’s worth watching as CBD could be the Next Big Thing!

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
CME Group
Back To Top